Literature DB >> 24517561

Prospective evaluation of metabolic syndrome and its components among long-term liver recipients.

Lucilene R Anastácio1, Kiara G Diniz, Hélem S Ribeiro, Lívia G Ferreira, Agnaldo S Lima, Maria Isabel T D Correia, Eduardo G Vilela.   

Abstract

BACKGROUND & AIMS: Survival after liver transplantation (LTx) has increased. Metabolic syndrome (MS) is widely reported in patients in the early years after LTx; few studies have researched this condition in relatively long-term liver recipients. To describe, prospectively, the prevalence of MS, its components and its associated factors in relatively long-term liver recipients.
METHODS: A total of 117 patients were evaluated in 2008 (median of 3 years after LTx, range 0-13 years) and in 2012 (median of 7 years after LTx, range 3-17 years) for the presence of MS [using modified NCEP Adult Treatment Panel III and International Diabetes Federation (IDF) criteria]; its components; and its associated factors, including demographic, socioeconomic, lifestyle, clinical, body composition (measured using bioelectric impedance) and dietetic factors.
RESULTS: MS increased over the years (IDF, 43.1-53.3%, P=0.12; and NCEP, 34.3-44.8%, P=0.03). Blood glucose increased over the years (98.8±24.7 to 109.2±33.3 mg/dl, P<0.01), which resulted in an increased prevalence of glucose intolerance (34.2-48.6%, P<0.01). Waist circumference (93.3±14.3 to 99.4±14.9 cm, P<0.01) and body fat (30.3±8.9 to 31.8±10.3%, P=0.03) also increased. The MS associated factors (P<0.05) were age [Odds ratio (OR) 1.05, confidence interval (CI) 1.02-1.11], family history of diabetes (OR 3.38, CI 1.19-9.61), body mass index (BMI) prior to liver disease (OR 1.39, CI 1.19-1.63) and body fat (OR 1.09, CI 1.03-1.14). The MS components were associated (P<0.05) with greater age, family history of diabetes, current and previous BMI, body fat, current corticosteroid use, lack of exercise and greater carbohydrate and fat intakes.
CONCLUSION: MS prevalence increased over the years after LTx because of the increases in waist circumference and blood glucose. MS and its components are associated with modifiable factors, such as greater BMI, body fat and carbohydrate and fat intake.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  diabetes mellitus; immunosuppressive agents; liver transplantation; metabolic syndrome; obesity

Mesh:

Substances:

Year:  2014        PMID: 24517561     DOI: 10.1111/liv.12495

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

Review 1.  Keys to long-term care of the liver transplant recipient.

Authors:  Kymberly D Watt
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-13       Impact factor: 46.802

Review 2.  Nutrition therapy: Integral part of liver transplant care.

Authors:  Lucilene Rezende Anastácio; Maria Isabel Toulson Davisson Correia
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 3.  Long-term Management of the Adult Liver Transplantation Recipients.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

4.  PREVALENCE AND RISK FACTORS OF HYPERKALEMIA AFTER LIVER TRANSPLANTATION.

Authors:  Helem Sena Ribeiro; Michelle Carvalho Oliveira; Lucilene Rezende Anastácio; Simone Vasconcelos Generoso; Agnaldo Soares Lima; Maria Isabel Correia
Journal:  Arq Bras Cir Dig       Date:  2018-06-21

Review 5.  Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation.

Authors:  Kinga Czarnecka; Paulina Czarnecka; Olga Tronina; Teresa Bączkowska; Magdalena Durlik
Journal:  Immun Inflamm Dis       Date:  2021-10-01

6.  Warm ischemia time and elevated serum uric acid are associated with metabolic syndrome after liver transplantation with donation after cardiac death.

Authors:  Liang-Shuo Hu; Yi-Chao Chai; Jie Zheng; Jian-Hua Shi; Chun Zhang; Min Tian; Yi Lv; Bo Wang; Ai Jia
Journal:  World J Gastroenterol       Date:  2018-11-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.